Suggested remit - To appraise the clinical and cost effectiveness of fostamatinib within its marketing authorisation for treating persistent or chronic immune thrombocytopenia.
 
Status In progress
Process STA 2018
ID number 1087

Provisional Schedule

Committee meeting: 1 14 October 2020
Expected publication 06 January 2021

Project Team

Project lead Jo Ekeledo

Email enquiries

Evidence Review Group / Assessment Group Health Economics Research Unit and Health Services Research Unit, University of Aberdeen

Consultees

Companies sponsors Grifols (fostamatinib)
Others Department of Health and Social Care
  NHS England
  NHS South Reading CCG
  NHS Swindon CCG
  Welsh Government
Patient carer groups ITP Support Association
  Muslim Council of Britain
  South Asian Health Foundation
  Specialised Healthcare Alliance
Professional groups Association of Surgeons of Great Britain and Ireland
  British Blood Transfusion Society
  British Committee for Standards in Haematology
  British Geriatric Society
  British Society for Haematology
  NHS Blood and Transplant
  Royal College of Anaesthetists
  Royal College of General Practitioners
  Royal College of Nursing
  Royal College of Pathologists
  Royal College of Physicians
  Royal College of Surgeons
  Royal Pharmaceutical Society
  Royal Society of Medicine
  United Kingdom Clinical Pharmacy Association
  UK ITP Forum

Commentators

Associated public health groups Public Health England
  Public Health Wales
Comparator companies Amgen (romiplostim)
  Napp Pharmaceuticals (rituximab)
  Novartis Pharmaceuticals (eltrombopag, ciclosporin)
  Roche (rituximab, mycophenolate mofetil)
  Sandoz (rituximab, cyclophosphamide)
  Accord UK (azathioprine, mycophenolate mofetil, vinorelbine)
  Mylan (azathioprine, ciclosporin, danazol, mycophenolate mofetil)
  Dexcel Pharma Ltd (ciclosporin)
  Ennogen (azathioprine)
  Aspen (azathioprine)
  Baxter Healthcare Ltd (cyclophosphamide)
  Sanofi (danazol)
  Accord UK (dapsone, vinorelbine)
  Teva Pharma BV (mycophenolate mofetil)
  Hospira UK Ltd (vinblastine, vincristine)
  Pierre Fabre (vinorelbine, vinflunine)
  Medac GmbH (vinorelbine)
  Consilient Health Ltd (vinorelbine)
  Genus Pharma (vindesine)
General commentators All Wales Therapeutics and Toxicology Centre
  Allied Health Professionals Federation
  Board of Community Health Councils in Wales
  British National Formulary
  Care Quality Commission
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Hospital Information Services – Jehovah’s Witnesses
  Medicines and Healthcare products Regulatory Agency National Association of Primary Care
  National Association of Primary Care
  National Pharmacy Association
  NHS Alliance
  NHS Confederation
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee
Relevant research groups Cochrane Haematological Malignancies Group
  Genomics England
  MRC Clinical Trials Unit
  National Institute for Health Research

Timeline

Key events during the development of the guidance:

Date Update
14 February 2020 Invitation to participate
14 February 2020 In progress, In progress
06 August 2019 - 04 September 2019 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
22 October 2018 The company that is developing fostamatinib have shared confidential information with NICE. As a result the Institute will not be progressing with the scoping exercise at this current time. Consequently the consultation on the draft scope will now be closed early. If you have any comments or concerns please contact the project manager for this proposed appraisal Emily Richards on (44 (0)161 413 4070 or via email on emily.richards@nice.org.uk

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance